Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Margot lived at the foot of Canyon Mountain, right outside of Livingston. Like much of Montana, the mountain was filled with wolves. But instead of fearing them, Margot loved them. She left meat out for the wolves so she could watch them come down the mountain and eat from the safety of her home ... She'd asked her closest friends—if they stopped by her place and found her dead—to tell no one, place her naked body in a bedsheet, drag it up Canyon Mountain, and leave her for her other friends, the wolves. Kidder's body was cremated, and the ashes were scattered by her brother John in her favorite childhood locations in Canada, as well as in Montana, amongst lilies which were frequently eaten by grizzly bears, partially fulfilling Kidder's wish to "have her body just left out there for the bears."
==== Infrastructure ==== The conflict resulted in widespread destruction in Lebanon that was particularly seen in the south, east, and Dahieh—the southern suburbs of the capital, Beirut. According to the World Bank, 99,209 houses were damaged during the conflict, of which 18% were destroyed. By 31 October 2024, nearly 25% of the buildings in towns near the border were damaged or destroyed, with the most destruction occurring in Kfar Kila and Ayta ash-Shaab. Roughly 80% of the damage occurred after 2 October. In the areas that the IDF had captured during its ground invasion into Lebanon, 42% of buildings were destroyed, according to NBC News. Amnesty International reported the damaging or destruction of over 10,000 buildings between October 2024 and January 2025, with 70% of the buildings in Yaroun, Dhayra, and Al-Bustan being severely damaged or destroyed. UN-Habitat reported that 27% of buildings in Marjayoun and 15% of buildings in Bint Jbeil were damaged or destroyed, while the mayor of Kfar Kila stated that 90% of the homes in the village were destroyed during the conflict, with the remaining 10% sustaining damage. The scale of destruction in Dahieh was comparable to the 2006 Lebanon war, with 353 buildings in the area being destroyed and more than 6,000 houses damaged. The Hezbollah-linked newspaper Al Akhbar reported that the cost of damages in Dahieh was $630 million. More than 60 schools have been destroyed since September 2024, according to Save the Children.
Low-level waste (LLW) is generated from hospitals and industry, as well as the nuclear fuel cycle. Low-level wastes include paper, rags, tools, clothing, filters, and other materials which contain small amounts of mostly short-lived radioactivity. Materials that originate from any region of an active area are commonly designated as LLW as a precautionary measure even if there is only a remote possibility of being contaminated with radioactive materials. Such LLW typically exhibits no higher radioactivity than one would expect from the same material disposed of in a non-active area, such as a normal office block. Example LLW includes wiping rags, mops, medical tubes, laboratory animal carcasses, and more. LLW makes up 94% of all radioactive waste volume in the UK. Most of it is disposed of in Cumbria, first in landfill style trenches, and now using grouted metal containers that are stacked in concrete vaults. A new site in the north of Scotland is the Dounreay site which is prepared to withstand a 4m tsunami.[1] Some high-activity LLW requires shielding during handling and transport but most LLW is suitable for shallow land burial. To reduce its volume, it is often compacted or incinerated before disposal. Low-level waste is divided into four classes: class A, class B, class C, and Greater Than Class C (GTCC).
=== Phase III ACHIEVE-1 trial === In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%. More than 65% of participants taking the highest dose of orforglipron achieved a reduction of hemoglobin A1C level by more than or equal to 1.5 percentage points, bringing them into the non-diabetic range as defined by the American Diabetes Association. People taking the highest dose of the pill lost 8% of their weight, or around 16 lb (7.3 kg), on average after 40 weeks. In its press release, Lilly noted that the subjects' weight loss had not yet plateaued at the time the trial concluded, and suggested that this indicated that greater weight reduction would ultimately be achieved with extended therapy. Side effects were similar to those seen with other GLP-1 agonists, and no significant liver problems were observed.
Sources: en.wikipedia.org
== Facilities == The Aga Khan University Hospital (AKUH) is a 720-bed quaternary care teaching hospital in Karachi, Pakistan. It provides all services under one roof. The hospital offers 96 private rooms, 210 semi-private rooms, 171 general ward beds, 166 special care beds, and 77 intensive care beds across its Intensive Care Unit (ICU), Coronary Care Unit (CCU), Neonatal Intensive Care Unit (NICU) and Paediatric Intensive Care Unit (PICU). In 2019, the hospital expanded its private facilities with the opening of the Princess Zahra Pavilion, oncampus. AKUH has 17 main operating theatres, two labour and delivery operating theatres and four day-care operating theatres where day-care surgery services, including minimally invasive surgeries are offered. The hospital offers a range of diagnostic and support services, including radiology (including nuclear medicine), laboratory medicine, pharmacy, cardiopulmonary services, neurophysiology, and physiotherapy and rehabilitation medicine.
Alexander Butlerov showed in 1861 that the formose reaction created sugars including tetroses, pentoses, and hexoses when formaldehyde is heated under basic conditions with divalent metal ions like calcium. R. Breslow proposed that the reaction was autocatalytic in 1959.
=== Aggregation === Tropoelastin aggregates at physiological temperature due to interactions between hydrophobic domains in a process called coacervation. This process is reversible and thermodynamically controlled and does not require protein cleavage. The coacervate is made insoluble by irreversible crosslinking.
== Further reading == William F. Neuman and Margaret W. Neuman. (1958). The Chemical Dynamics of Bone Mineral. Chicago: The University of Chicago Press. ISBN 0-226-57512-8. Netter, Frank H. (1987). Musculoskeletal system: anatomy, physiology, and metabolic disorders. Summit, New Jersey: Ciba-Geigy Corporation ISBN 0-914168-88-6.
=== Musculoskeletal === Musculoskeletal symptoms include hyperflexible joints that are unstable and prone to sprain, dislocation, subluxation, and hyperextension. As a result of frequent tissue injury, there can be an early onset of advanced osteoarthritis, chronic degenerative joint disease, swan-neck deformity of the fingers, and Boutonniere deformity of the fingers. Tendon and ligament laxity offer minuscule protection from tearing in muscles and tendons, but these problems persist. Deformities of the spine, such as scoliosis (curvature of the spine), kyphosis (a thoracic hump), tethered spinal cord syndrome, craniocervical instability (CCI), and atlantoaxial instability may also be present. Osteoporosis and osteopenia are also associated with EDS and symptomatic joint hypermobility. There can also be myalgia (muscle pain) and arthralgia (joint pain), which may be severe and disabling. Trendelenburg's sign is often seen, which means that when standing on one leg, the pelvis drops on the other side. Osgood–Schlatter disease, a painful lump on the knee, is common as well. In infants, walking can be delayed (beyond 18 months of age), and bottom-shuffling instead of crawling occurs.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.